consider this independent network meta-analysis when choosing an SGLT2i1

SGLT2i network meta-analysis study design1

Objective Indirectly assess comparative efficacy and safety of SGLT2 inhibitors in patients with type 2 diabetes
Treatments INVOKANA® (canagliflozin), Jardiance® (empagliflozin), Farxiga® (dapagliflozin)
Studies analyzed 38 randomized, placebo-controlled trials published up to November 3, 2015
Duration of studies 24 weeks
Number of patients (overall) 23,997
Outcomes 1 cardiometabolic or safety outcomes

The number of available studies analyzed may vary by outcome endpoint.

Limitations of the network meta-analysis1:

  • Data were sourced only from journal articles or from ClinicalTrials.gov, which could risk publication bias
  • In some studies, outcomes may not be reported or it may not be possible to extract them in a suitable way; however, information was retrieved from all 38 trials for A1C and from 37 trials for body weight
  • Across randomized controlled trials, ethnicities of participants, follow-up durations, outcomes selection, definition, and ascertainment could differ; however, the authors deemed the network used in this analysis as consistent for A1C outcomes

 

There have been no head-to-head clinical trials comparing the efficacy or safety of SGLT2 inhibitors. No direct evaluation of comparative clinical profiles can be made.

 

Placebo-adjusted mean change in A1C (%) from an average mean baseline of 8.1%1

  • Results from an independent network meta-analysis, including 38 randomized controlled studies (body weight data from 37 studies, systolic BP data from 33 studies), which ranged in duration from 24 to 208 weeks1

The recommended starting dose of INVOKANA® is 100 mg once daily.2

BP=blood pressure; SGLT2i=sodium-glucose co-transporter 2 inhibitor.

Data reported are mean differences vs placebo (95% CI).

*Change in A1C was significantly greater with INVOKANA® 300 mg vs comparator.

 

INVOKANA® 300 mg:
Statistically significantly greater A1C reductions than Farxiga® 10 mg and Jardiance® 25 mg1

Placebo-adjusted mean change in body weight from baseline (lb)1

 

  • Results from an independent network meta-analysis, including 38 randomized controlled studies (body weight data from 37 studies, systolic BP data from 33 studies), which ranged in duration from 24 to 208 weeks1

BP=blood pressure; SGLT2i=sodium-glucose co-transporter 2 inhibitor.

Data reported are mean differences vs placebo (95% CI).

INVOKANA® is not indicated for weight loss.

Placebo-adjusted mean change in systolic BP from baseline (mm Hg)1

 

  • Results from an independent network meta-analysis, including 38 randomized controlled studies (body weight data from 37 studies, systolic BP data from 33 studies), which ranged in duration from 24 to 208 weeks1

BP=blood pressure; SGLT2i=sodium-glucose co-transporter 2 inhibitor.

Data reported are mean differences vs placebo (95% CI).

*Change in systolic BP was significantly greater with INVOKANA® 300 mg vs comparator.

INVOKANA® is not indicated as an antihypertensive treatment.

References: 1. Zaccardi F, Webb DR, Htike ZZ, Youssef D, Khunti K, Davies MJ. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes Obes Metab. 2016;18(8):783-794. 2. INVOKANA® [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.